CD19 CAR-T has been shown to be efficacious in treating B-cell malignancies, with a CR rate as high as 90% for B-ALL, and 60% for B-NHL, respectively, when evaluated about 1 month following infusion (1–3). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.